About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Menu
About Us
Our Company
Leadership
Compliance
Contact
Medical Education Grants
Our
Medicines
YCANTH
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline VP-315
R & D
Key Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
For information about YCANTH™ or to request a representative, visit YCANTHPro.com
Press Releases
Press Releases
Year
2018
2019
2020
2021
2022
2023
2024
2025
Submit
January 21, 2025
Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP 315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference
